stockrowTrulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
Follow TRLV
Alert me
Trulieve Cannabis Corp. (TRLV) Net income
Trulieve Cannabis Corp.'s net income for fiscal 2025 was −$122.2M, compared with −$160.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$446.6M. Over the past ten years it has ranged from −$533.1M (fiscal 2023) to $63.0M (fiscal 2020); the current reading is higher than 67% of that period. Trulieve Cannabis Corp. ranks 82nd of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$122.2M | — |
| FY2024 | −$160.6M | — |
| FY2023 | −$533.1M | — |
| FY2022 | −$252.7M | — |
| FY2021 | $17.4M | (72.31%) |
| FY2020 | $63.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $774.0K | — |
| Jun 2026 | −$406.1M | — |
| Mar 2026 | $2.3M | — |
| Dec 2025 | −$43.6M | — |
| 19 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| ANIP ANI Pharmaceuticals, Inc. compare | $116.8M |
| XERS Xeris Biopharma Holdings, Inc. compare | −$6.5M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| ALVO Alvotech compare | −$179.6M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$359.7M |
| TRLV Trulieve Cannabis Corp. | −$446.6M |
| PRGO Perrigo Company plc compare | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on TRLV
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement